RAD9A

Across TCGA pan-cancer cohorts, RAD9A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAD9A data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RAD9A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD9A expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where RAD9A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.841	0.583	.001	35	view →
LUAD	OS	Median	II,III,IV	1.000	0.818	.016	7	view →
PDAC	DFS	Tertile	IV	0.777	0.221	.024	5	view →
CCRCC	DFS	Median	All	0.885	0.978	.028	4	view →
UCEC	DFS	Tertile	All	0.947	0.793	.031	2	view →
GBM	DFS	Median	All	0.403	0.239	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAD9A–LSCC (DFS)

Open the LSCC breakdown →